Daniel Barber - 07 Mar 2025 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Reporting relationship: President and CEO
Issuer ticker: AQST
Reported as of: 07 Mar 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Apr 2026, 15:54:35 UTC
Prior SEC filing: 02 Oct 2024
Next SEC filing: 22 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Lori Braender, as Attorney-In-Fact

Key filing fact

Daniel Barber filed Form 4 for Aquestive Therapeutics, Inc. (AQST) on 13 Apr 2026.

Key facts

This page summarizes Daniel Barber's Form 4 filing for Aquestive Therapeutics, Inc. (AQST).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Apr 2026, 15:54.

Change

Previous filing in this sequence was filed on 02 Oct 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001742266 Primary reporting owner

Barber Daniel

Relationship: President and CEO
Address: C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN
Signature: /s/ Lori Braender, as Attorney-In-Fact
Signature date: 13 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AQST transaction Derivative

Performance Stock Units

Award

Transaction value
Shares: +293,100
Change %
Price: $0.000000^*
Shares after: 293,100
Date: 07 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 293,100
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This Form 4 was filed late due to an inadvertent administrative oversight.

Footnote F2

Each PSU represents a contingent right to receive one share of the Company's common stock. The PSUs measure performance from March 7, 2025 (Grant Date) through March 7, 2028 and, if earned, vest 100% on March 7, 2028. "Performance Price" means (i) the 30-day average Nasdaq closing price ending on the last day of the period from the Grant Date through the day before the second anniversary (First Pricing Period) and (ii) the highest 30-day average Nasdaq closing price during the period from the second through the third anniversary (Second Pricing Period).